Three BiTEs set to disrupt r/r multiple myeloma space with $9 billion sales by 2030

9 May 2024

Recent developments in the field of bispecific T-cell engagers (BiTEs) have led to the approval of three therapies for relapsed/recurrent multiple myeloma (RRMM).

These are: Pfizer’s (NYSE: PFE) Elrexfio (elranatamab); and Tecvayli (teclistamab) and Talvey (talquetamab) both developed by Johnson & Johnson (NYSE: JNJ).

Clinical data of the three have been surprising, surpassing previously anticipated response rates. With an ever-growing number of patients entering the RRMM population, these BiTEs are poised to become the pre-eminent therapeutic option, recording sales of nearly $9 billion by 2030, according to pharma analytics company GlobalData.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK